Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
961 Mannitol 20% Injection (20 g/100 ml) B05BC01-000-P30-02-XXX A Cerebral oedema - 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age
962 Measles and Rubella Virus Live, Attenuated Vaccine Injection J07BD52-963-P40-02-XXX C+ Immunisation against measles and rubella. - 0.5ml by deep SC injection. Dosing is according to Immunisation Schedule under NIP and product insert.
963 Measles Vaccine Injection J07BD01-000-P40-01-XX C+ Immunisation against measles. - 0.5ml by SC or IM. Dosing is according to Immunisation Schedule under NIP.
964 Measles, Mumps and Rubella (MMR) Vaccine Injection J07BD52-963-P40-01-XXX C+ For immunisation of children against measles, mumps and rubella - 0.5ml by SC or IM. Dosing is according to Immunisation Schedule under NIP.
965 Mebeverine HCl 135mg Tablet A03AA04-110-T10-02-XXX B i) Irritable bowel syndrome
ii) Treatment of gastro-intestinal spasm secondary to organic diseases.		 - 135 mg 3 times daily
966 Meclozine HCl 25mg and Pyridoxine 50mg Tablet R06AE55-919-T10-01-XXX B Nausea and vomiting of pregnancy None Optimum dosing: 1 to 2 tablets OD. Maximum dosing: 4 tablets/day.
967 Mecobalamin 500mcg Tablet M09AX00-000-T10-01-XXX B Peripheral neuropathies - 1 tablet 3 times daily. The dosage should be adjusted according to age of patient and severity of symptoms
968 Medroxyprogesterone Acetate 100 mg Tablet L02AB02-122-T10-02-XXX A Breast carcinoma, endometrial carcinoma, renal carcinoma - 200-500 mg orally daily
969 Medroxyprogesterone Acetate 10mg Tablet G03DA02-122-T10-02-XXX B i) Secondary amenorrhoea
ii) Abnormal uterine bleeding due to hormonal imbalance		 None i) 5-10 mg daily for 5-10 days started anytime during cycle
ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
970 Medroxyprogesterone Acetate 500 mg Tablet L02AB02-122-T10-01-XXX A Breast carcinoma, endometrial carcinoma, renal carcinoma - 200-500 mg orally daily
971 Medroxyprogesterone Acetate 50mg/ml Injection G03AC06-122-P30-01-XXX B Prevention of pregnancy and to provide long term contraception None 150mg to be administered once every 3 month
972 Medroxyprogesterone Acetate 5mg Tablet G03DA02-122-T10-01-XXX B i) Secondary amenorrhoea
ii) Abnormal uterine bleeding due to hormonal imbalance		 None i) 5-10 mg daily for 5-10 days started anytime during cycle
ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
973 Mefenamic Acid 250mg Capsule M01AG01-000-C10-01-XX C Mild to moderate pain None ADULT: 250 - 500 mg 3 times daily after meals.
974 Mefenamic Acid 250mg Tablet M01AG01-000-T10-01-XXX C Mild to moderate pain None ADULT: 250 - 500 mg 3 times daily after meals.
975 Mefloquine HCl 250mg Tablet P01BC02-110-T10-01-XXX A* For multi-drug resistant cases of malaria only None Treatment of malaria : ADULT and CHILD 25 mg/kg usually given over 2-3 days. Prophylaxis of malaria : ADULT 250 mg once a week. CHILD over 5 kg : 5 mg/kg once a week; prophylaxis should start 1-3 weeks before departure and continue for 4 weeks after last exposure
976 Meloxicam 7.5mg Tablet M01AC06-000-T10-01-XXX A/KK Only for patients not responding to other NSAIDs in the treatment of:
i) painful osteoarthritis
ii) rheumatoid arthritis		 - i) initially 7.5 mg daily. May be increased to 15 mg daily
ii) initially 15 mg daily. May be reduced to 7.5 mg daily. Maximum 15 mg daily. Child under 12 years not recommended
977 Melphalan 2 mg Tablet L01AA03-000-T10-01-XXX A i) Multiple myeloma
ii) Neuroblastoma, rhabdomyosarcoma
iii) Recurrent neuroblastoma (palliative)		 i) 8 - 10 mg/m2 for 4 days every 4 weeks
ii) 10 - 35 mg/m2 once every month

For dose regimes, refer to protocols
978 Melphalan 50 mg Injection L01AA03-000-P40-01-XXX B High dose conditioning therapy for stem cell transplantation in multiple myeloma - 200 mg/ m2 IV infusions in divided doses for Day 1 to day 3 followed by IV infusions of autologous stem cells
979 Memantine HCI 10mg Tablet N06DX01-110-T10-01-XXX A* Treatment of moderate to severe Alzheimer's disease. - Initial
Week 1: 5mg daily
Week 2: 10mg daily
Week 3: 15mg daily
Week 4 and subsequent: 20mg daily

Maintenance 20mg daily

Max. dose: 20mg daily
980 Memantine HCl 20 mg Tablet N06DX01-110-T10-02-XXX A* Treatment of moderate to severe Alzheimer's disease - nitial
Week 1: 5mg daily
Week 2: 10mg daily
Week 3: 15mg daily
Week 4 and subsequent: 20mg daily

Maintenance 20mg daily

Max. dose: 20mg daily
981 Meningococcal Group A, C, Y, W 135 Vaccine Injection J07AH04-000-P40-01-XXX B Immunisation against meningococcal diseases caused by Neisseria meningitis Group A, Group C, Group Y or Group W-135. - 0.5ml by IM.
982 Menotrophin (highly purified, multidose) 600IU injection G03GA02-000-P40-01-XXX A* For the treatment of infertility in the following clinical situations:
i. Anovulation, including polycystic ovarian syndrome (PCOS), in women who have been unresponsive to treatment with clomiphene citrate.
ii. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART).		 None i. Recommended starting dose: 75-150 IU daily, maintaining the starting dose for at least 7 days. Adjust the dose according to individual response at a minimum interval of 7 days. The recommended dose increment is 37.5 -75 IU per adjustment. Maximum daily dose: 225 IU.

ii. Recommended starting dose: 150-225 IU daily, maintaining the starting dose for at least the first 5 days of treatment. Adjust the dose according to individual response. The dose increment should not exceed more than 150 IU per adjustment. Maximum daily dose: 400 IU.

Dosing is individualised and according to product insert/protocol
983 Menotrophin, highly purified 150 IU injection G03GA02-954-P40-02-XXX A* i) Anovulation in women who have been unresponsive to treatment with clomiphene citrate
ii) Stimulation of follicle growth as part of an assisted reproductive technology (ART)		 - i) Anovulation in women who have been unresponsive to treatment with clomiphene citrate:
The recommended initial dose is 75-150 IU daily, which should be maintained for at least 7 days. The subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should recommence treatment at a higher starting dose than in the abandoned cycle.

When an optimal response is obtained, a single injection of 5,000 IU to 10,000 IU of Human Chorionic Gonadotrophin (hCG) should be given 1 day after the last menotrophin injection, The patient is recommended to have coitus on the day of and the day following hCG administration.

ii) Stimulation of follicle growth as part of an assisted reproductive technology (ART):
The recommended initial dose is 150-225IU daily injection for at least the first 5 days of treatment. Based on clinical monitoring subsequent dosing should be adjusted according to individual patient response and should not exceed more than 150IU per adjustment. The maximum daily dose should not be higher than 450 IU. In most cases, dosing beyond 20 days is not recommended.
984 Menotrophin, Highly Purified 75 IU Injection (Follicle Stimulating Hormone 75 IU and Luteinizing Hormone 75 IU) G03GA02-954-P40-03-XXX A* For the treatment of infertility in the following clinical situations:
i. Anovulation, including polycystic ovarian syndrome (PCOS), in women who have been unresponsive to treatment with clomiphene citrate.
ii. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART).		 - i. Recommended starting dose: 75-150 IU daily, maintaining the starting dose for at least 7 days. Adjust the dose according to individual response at a minimum interval of 7 days. The recommended dose increment is 37.5 -75 IU per adjustment. Maximum daily dose: 225 IU.

ii. Recommended starting dose: 150-225 IU daily, maintaining the starting dose for at least the first 5 days of treatment. Adjust the dose according to individual response. The dose increment should not exceed more than 150 IU per adjustment. Maximum daily dose: 400 IU.

Dosing is individualised and according to product insert/protocol
985 Mepivacaine HCl 2% with Adrenaline (1:100,000) Injection N01BB53-974-P30-01-XXX B For the production of local anaesthesia for dental procedures including infiltration and nerve blocks - ADULT: 2.2ml for routine procedure. Max: 3 cartridges.

CHILD:
6-14 years: 1.6ml. Max: 3.3mL. 3-6 years 1.1 to 2.2ml.

Dosing is according to product insert.
986 Mepivacaine HCl 3% Injection N01BB03-110-P30-01-XXX B For the production of local anaesthesia for dental procedures by infiltration injection or nerve block. - ADULT: 1 cartridge for routine procedure. Max: 3 cartridges.

CHILD:
6-14 years: 1.35ml. Max: 2.7ml. 3-6 years: maximum 1.8ml.

Dosing is according to product insert
987 Mercaptopurine 50 mg Tablet L01BB02-000-T10-01-XXX A i) Langerhan’s cell histiocytosis (LCH)
ii) Treatment of acute leukemia in adults, adolescents and children		 None Adults and paediatric population:
For adults and children the usual dose is 2.5 mg/kg bodyweight per day, or 50 to 75 mg/m2 body surface area per day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction with 6-mercaptopurine.

The dosage should be carefully adjusted to suit the individual patient.
988 Meropenem 1g Injection J01DH02-000-P40-02-XXX A* i) Nosocomial pneumonia
ii) Bacterial Meningitis
iii) Empirical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent
iv) Septicaemia
v) Urinary tract infections
vi) Intra-abdominal infections
vii) Gynaecological infections		 None ADULT: 1-2g every 8hourly (refer to specific indication dosing)
CHILD (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used.

Dosing is according to product insert/ protocol.
989 Meropenem 500mg Injection J01DH02-000-P40-01-XXX A* i) Nosocomial pneumonia
ii) Bacterial Meningitis
iii) Empirical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent
iv) Septicaemia
v) Urinary tract infections
vi) Intra-abdominal infections
vii) Gynaecological infections		 None ADULT: 1-2g every 8hourly (refer to specific indication dosing)
CHILD (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used.

Dosing is according to product insert/ protocol.
990 Mesalazine 1 g Suppository A07EC02-259-S20-02-XXX A Inflammatory bowel disease of ulcerative colitis and Crohn's disease. - Ulcerative colitis: 1 g suppository insert rectally once daily at bedtime. To achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks.
CHILD not recommended

Pages